FATE
Fate Therapeutics Inc.
Company Overview
| Mkt Cap | $137.24M | Price | $1.15 |
| Volume | 1.41M | Change | +3.60% |
| P/E Ratio | -0.7 | Open | $1.12 |
| Revenue | $13.6M | Prev Close | $1.11 |
| Net Income | $-186.3M | 52W Range | $0.66 - $2.93 |
| Div Yield | N/A | Target | $4.94 |
| Overall | 44 | Value | 60 |
| Quality | 36 | Technical | 36 |
No chart data available
About Fate Therapeutics Inc.
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, and FT825 to treat solid tumors.It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Latest News
Fate Therapeutics Reports Q3 Loss Amid Restructuring Efforts
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), ALX Oncology Holdings (ALXO) and 60 Degrees Pharmaceuticals, Inc. (SXTP)
Navigating Data Privacy Challenges: Fate Therapeutics’ Battle with Regulatory Compliance and Business Risks
Fate Therapeutics (FATE) Receives a Hold from Bank of America Securities
Analysts Have Conflicting Sentiments on These Healthcare Companies: Indaptus Therapeutics (INDP) and Fate Therapeutics (FATE)
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | FATE | $1.15 | +3.6% | 1.41M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |